Beone Medicines LTD. revenue by year
Over the 10 fiscal years shown, revenue went from $1.07M (year ended Dec 31, 2016) to $5.34B (year ended Dec 31, 2025), a compound annual growth rate of 157.6%. The fastest growth was +22179.2% in the year ended Dec 31, 2017; the weakest year was −27.9% (year ended Dec 31, 2020).
Annual revenue
| Fiscal year ended | Revenue (USD) | Change | XBRL concept | Reported in |
|---|---|---|---|---|
| Dec 31, 2025 | $5.34B | +40.2% | RevenueFromContractWithCustomerExcludingAssessedTax | 10-K filed Feb 26, 2026 |
| Dec 31, 2024 | $3.81B | +55.0% | RevenueFromContractWithCustomerExcludingAssessedTax | 10-K filed Feb 26, 2026 |
| Dec 31, 2023 | $2.46B | +73.7% | RevenueFromContractWithCustomerExcludingAssessedTax | 10-K filed Feb 26, 2026 |
| Dec 31, 2022 | $1.42B | +20.4% | RevenueFromContractWithCustomerExcludingAssessedTax | 10-K filed Feb 27, 2025 |
| Dec 31, 2021 | $1.18B | +280.8% | RevenueFromContractWithCustomerExcludingAssessedTax | 10-K filed Feb 26, 2024 |
| Dec 31, 2020 | $308.87M | −27.9% | RevenueFromContractWithCustomerExcludingAssessedTax | 10-K filed Feb 27, 2023 |
| Dec 31, 2019 | $428.21M | +116.0% | RevenueFromContractWithCustomerExcludingAssessedTax | 10-K filed Feb 25, 2021 |
| Dec 31, 2018 | $198.22M | −16.8% | RevenueFromContractWithCustomerExcludingAssessedTax | 10-K filed Feb 25, 2021 |
| Dec 31, 2017 | $238.39M | +22179.2% | Revenues | 10-K filed Feb 28, 2018 |
| Dec 31, 2016 | $1.07M | −87.9% | Revenues | 10-K filed Feb 28, 2018 |
Beone Medicines LTD. reported revenue under 2 different XBRL concepts across these years (often after the 2018 change in revenue-recognition rules, ASC 606). Each row shows the concept used, so you can judge comparability.
Quarterly revenue
Quarters reported in 10-Q filings. Fourth quarters are usually reported only inside the annual 10-K, so they are not listed separately here; we do not estimate them.
| Quarter | Revenue (USD) | vs same quarter a year earlier | Source |
|---|---|---|---|
| 3 months ended Jun 30, 2026 | $1.71B | +29.6% | 10-Q filed Aug 5, 2026 |
| 3 months ended Mar 31, 2026 | $1.51B | +35.5% | 10-Q filed May 6, 2026 |
| 3 months ended Sep 30, 2025 | $1.41B | +41.0% | 10-Q filed Nov 6, 2025 |
| 3 months ended Jun 30, 2025 | $1.32B | +41.6% | 10-Q filed Aug 5, 2026 |
| 3 months ended Mar 31, 2025 | $1.12B | +48.6% | 10-Q filed May 6, 2026 |
| 3 months ended Sep 30, 2024 | $1.00B | +28.2% | 10-Q filed Nov 6, 2025 |
| 3 months ended Jun 30, 2024 | $929.17M | +56.1% | 10-Q filed Aug 6, 2025 |
| 3 months ended Mar 31, 2024 | $751.65M | +67.9% | 10-Q filed May 7, 2025 |
Source: SEC EDGAR XBRL company facts for CIK 1651308 (raw data). Most recent filing in this dataset: 10-Q filed Aug 5, 2026. SEC data file dated Nov 3, 2026; page built Nov 5, 2026. Figures are as most recently reported, including restatements. How we select figures.